<DOC>
	<DOCNO>NCT00989768</DOCNO>
	<brief_summary>The objective study compare field effect botulinum toxin ( Dysport® Botox® ) use two equivalence-ratios gather supportive information , detail data effectiveness reduction wrinkle duration action upper part face product , trough scale photographs evaluation .</brief_summary>
	<brief_title>Field Effects Two Commercial Preparations Botulinum Toxin Type A</brief_title>
	<detailed_description>This monocentric , prospective , randomize double-blind study . Twenty nine female patient , present moderate severe forehead wrinkle , sweat ability never undergone previous BoNT-A injection enrol . Subjects receive botulinum toxin type-A injection two forehead site , Botox 2U Dysport 5U , reconstitute volume 0.02 mL per point . Baseline , twenty-eight 112 day later , clinical photographic assessment , Minor´s test , electromyographic ( EMG ) evaluation perform .</detailed_description>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>1 . Written Informed Consent ( Annex 1 ) 2 . Female 3 . Subjects agree take part procedure study , include botulinum toxin application , Minor 's test , measurement Evoked Potentials , photograph , etc . ) , fully inform objective nature investigation 4 . Subjects age 18 60 year 5 . Subjects present moderate severe wrinkle forehead maximum voluntary contraction m. frontalis 6 . Subjects positive Minor 's test showing sweat forehead standardized condition describe Annex 2 *The Minor 's Test last inclusion criterion evaluate . Only patient eligible accord inclusion criterion undergo Minor 's Test evaluate sweat forehead . The cut point positive Minor 's Test ( Level +1 ) subject Minor 's Test ( Level +1 ) recruit study ( Annex 2 ) . 7 . Medical history physical examination , base investigator 's opinion , prevent patient take part study use product investigation 8 . Subjects childbearing age present negative urine pregnancy test baseline use effective contraceptive method ; 9 . Availability patient throughout duration study ( 112 day ) 10 . Subject agree undergo cosmetic dermatological procedure study 11 . Subjects sufficient school awareness enable cooperate degree require protocol 1 . Pregnant woman woman intend become pregnant next 4 month screen eligibility 2 . Subjects lactate 3 . Subjects undergone botulinum toxin treatment within last 6 month 4 . Subjects participate clinical trial 5 . Any prior surgery affect frontalis and/or orbicularis muscle , prior blepharoplasty brow lift 6 . Any prior cosmetic procedure , include filler , scar may interfere study result 7 . Subjects present frontoparietal alopecia accord NorwoodHamilton classification 8 . Subjects neoplastic , muscular neurological disease 9 . Subjects use aminoglycoside penicillamine antibiotic , quinine Ca2+ channel blocker 10 . Subjects inflammation active infection area inject 11 . Subjects present evident facial asymmetry 12 . Subjects history adverse effect , sensitivity component formula , ptosis adverse effect , investigator 's opinion prevent patient participate study 13 . Subjects present myasthenia gravis , EatonLambert Syndrome motor neuron diseases 14 . Subjects coagulation disorder use anticoagulant 15 . Subjects know systemic autoimmune diseases 16 . Subjects history medical treatment nonadherence show unwillingness adhere study protocol 17 . Any condition , opinion investigator , compromise evaluation study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Botulinum toxin type A</keyword>
	<keyword>field effect</keyword>
	<keyword>dose-equivalence</keyword>
	<keyword>anhydrotic action halo</keyword>
</DOC>